

# Hematology Market to Grow at 7.80% CAGR Through 2027 Backed by Rising Demand for Diagnostic Tools | Coherent Market

Hematology Market Research Report Information By Product Type, By Reagent, By Application, By End User, And By Region

GA, UNITED STATES, June 13, 2025 /EINPresswire.com/ -- <u>Hematology</u> <u>Market</u> Insights

The Global Hematology market size is estimated to be valued at USD 7.12 billion in 2025 and is expected to reach USD 12.07 billion by 2032, exhibiting a



compound annual growth rate (CAGR) of 7.80% from 2025 to 2032. This data-backed market forecast reflects our in-house market research and offers unique market insights into technology-driven business growth, market scope, and evolving industry trends.

#### Two market trends:

- Widespread adoption of Al-driven analyzers accelerated diagnostic throughput by 24% in 2024.
- Integration of point-of-care hematology testing expanded access in emerging Asia Pacific clinics.

☐Request Sample Copy of this Report (Use Corporate eMail ID to Get Higher Priority) at: <a href="https://www.coherentmarketinsights.com/insight/request-sample/943">https://www.coherentmarketinsights.com/insight/request-sample/943</a>

## **Key Takeaways**

- North America: Leading adoption of automated flow cytometers in major hospital networks.
- Latin America: Expanding primary care penetration via mobile hematology labs.

- Europe: Rapid uptake of multiplexed immunoassays in oncology clinics.
- Asia Pacific: Government subsidies boosted point-of-care hematology devices by 18% in 2024.
- Middle East: Public-private partnerships funded rural diagnostic centers.
- Africa: NGO-backed screening camps heightened demand for portable analyzers.
- By Product Type: Benchtop analyzers, reagents, and disposables—e.g., Roche's 2024 reagent kit for anemia screening.
- By End User: Hospitals, independent labs, and blood banks—e.g., Mindray's handheld analyzer in mobile blood drives.
- By Technology: Flow cytometry, microfluidics, and digital hematology—e.g., Siemens' IoT-based digital slide scanning.

# **Key Players**

- Abbott Laboratories, Sysmex Corporation, Beckman Coulter, Horiba Ltd., Boule Diagnostics AB, Mindray Medical International, Siemens Healthcare, Roche Diagnostics, Bio-Rad Laboratories, Sigma-Aldrich Co., Nihon Kohden Corporation, Becton Dickinson.
- Abbott's 2024 launch of the Alinity h3 analyzer increased throughput by 30% and captured new hospital contracts in North America.
- Roche's 2025 partnership with a genomics firm expanded its hematology reagent portfolio, resulting in a 15% revenue uplift.
- Sysmex's strategic R&D investment in AI algorithms improved differential count accuracy by 18%, reinforcing its competitive edge.

### **Growth Factors**

- Rising prevalence of hematological disorders—WHO reported a 12% increase in global anemia cases in 2024, driving demand for routine blood panels.
- Surge in point-of-care testing—over 30% of Asia Pacific clinics adopted handheld analyzers in 2025, fueling market growth strategies.
- Increasing R&D investment—Abbott Laboratories allocated USD 120 million to AI-powered reagent development in 2024, boosting throughput by 28%.

• Government healthcare funding—EU's Horizon Europe program granted USD 45 million for hematology diagnostics, underscoring market drivers and business growth opportunities.

☐ Book the Latest Edition of this Market Study Get Up to 25 % Discount @ <a href="https://www.coherentmarketinsights.com/insight/buy-now/943">https://www.coherentmarketinsights.com/insight/buy-now/943</a>

#### **Market Trends**

- Al-enabled diagnostics: Sysmex's 2024 algorithm reduced manual slide reviews by 40%, redefining market dynamics.
- Cloud-based data management: Beckman Coulter's 2025 digital platform integrated with hospital EMRs for real-time analytics.
- Point-of-care decentralization: Horiba's portable analyzer saw a 22% sales rise in rural India in 2024.
- Personalized medicine: Roche's next-gen hematology panels guided targeted therapies in 15 major oncology centers in 2025, illustrating evolving market opportunities and industry trends.

## **Actionable Insights**

- Production Capacity: Global hematology analyzer output grew to 85,000 units in 2024, up 14% year-on-year.
- Pricing Dynamics: Average street price for a benchtop analyzer fell 5% in 2025, intensifying market challenges for smaller players.
- Exports: China's reagent exports reached USD 220 million in H1 2024, marking a 32% surge.
- Imports: US imported hematology reagents valued at USD 180 million in 2024, reflecting strong demand in clinical labs.
- Use-Case Penetration: Blood banks accounted for 28% of total analyzer installs in 2025, driven by donation screening needs.
- Micro-indicators: Reagent lot failure rates dropped from 2.8% to 1.9% in 2024, enhancing overall test reliability.

☐☐ Book the Latest Edition of this Market Study Get Up to 25 % Discount @ <a href="https://www.coherentmarketinsights.com/insight/buy-now/943">https://www.coherentmarketinsights.com/insight/buy-now/943</a>

☐ Frequently Asked Questions

1. Who are the dominant players in the Hematology Market?

Leading market players include Abbott Laboratories, Sysmex, Roche Diagnostics, and Siemens Healthcare, which collectively drive technological innovation.

2. What will be the size of the Hematology Market in the coming years?

The Hematology Market size is projected to grow from USD 7.12 billion in 2025 to USD 12.07 billion by 2032 at a 7.80% CAGR.

3. Which end-user industry has the largest growth opportunity?

Hospitals and blood banks present the largest opportunity, accounting for over 60% of installations in 2024 due to routine screening demands.

4. How will Hematology Market trends evolve over the next five years?

Expect Al-enabled diagnostics, cloud integration, and personalized hematology panels to dominate market trends through 2030.

5. What is the nature of the competitive landscape and challenges in the Hematology Market?

Competition centers on pricing pressure, regulatory approvals, and technological differentiation, with smaller labs facing margin constraints.

6. What go-to-market strategies are commonly adopted in the Hematology Market?

Key strategies include strategic partnerships (e.g., Roche's genomics tie-up), localized manufacturing to optimize pricing, and subscription-based reagent models.

□□ Authored by:

Alice Mutum brings over 7 years of experience in healthcare journalism and data-focused content creation. Her expertise ensures each report is both scientifically grounded and aligned with the strategic needs of healthcare professionals.

**About Coherent Market Insights** 

Coherent Market Insights is a leading provider of Hematology Market intelligence and strategic advisory services. We specialize in pharmaceuticals, diagnostics, medtech, and digital

health—offering actionable insights to enhance business growth, regulatory planning, and patient care. Our global presence includes offices in the U.S., U.K., India, and Japan.

Mr. Shah
Coherent Market Insights Pvt. Ltd.
+1 252-477-1362
email us here
Visit us on social media:
LinkedIn
Facebook
X

This press release can be viewed online at: https://www.einpresswire.com/article/821888290

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.